CISATRACURIUM BESYLATE INJECTION SOLUTION

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Dostupné z:

ACCORD HEALTHCARE INC

ATC kód:

M03AC11

INN (Medzinárodný Name):

CISATRACURIUM

Dávkovanie:

2MG

Forma lieku:

SOLUTION

Zloženie:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Spôsob podávania:

INTRAVENOUS

Počet v balení:

10 ML

Typ predpisu:

Prescription

Terapeutické oblasti:

NEUROMUSCULAR BLOCKING AGENTS

Prehľad produktov:

Active ingredient group (AIG) number: 0133260001; AHFS:

Stav Autorizácia:

APPROVED

Dátum Autorizácia:

2016-09-01

Súhrn charakteristických

_Cisatracurium Besylate Injection_
_ Product Monograph Page 1 of 32 _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION
Solution for injection; 20 mg / 10 mL (2 mg / mL) cisatracurium (as
cisatracurium besylate)
(Multiple dose vial)
House Standard
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Sterile solution
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS, AND HAZARDS.
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC H9H 5B9
Canada
Submission Control No: 180494
Date of Preparation:
August 31, 2016
_Cisatracurium Besylate Injection_
_ Product Monograph Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
................................................................................................3
WARNINGS AND
PRECAUTIONS...............................................................................4
ADVERSE
REACTIONS.................................................................................................9
DRUG INTERACTIONS
................................................................................................10
DOSAGE AND ADMINISTRATION
............................................................................11
OVERDOSAGE
..............................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
..........................................................17
STORAGE AND
STABILITY........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.....................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................